Current Challenges and Opportunities for Improved Cannabidiol Solubility.
CBD
bioavailability
cannabidiol
solubility
stability
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
25 Sep 2023
25 Sep 2023
Historique:
received:
24
08
2023
revised:
20
09
2023
accepted:
22
09
2023
medline:
1
11
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Cannabidiol (CBD), derived from the cannabis plant, has gained significant attention due to its potential therapeutic benefits. However, one of the challenges associated with CBD administration is its low bioavailability, which refers to the fraction of an administered dose that reaches systemic circulation. This limitation necessitates the exploration of various approaches to enhance the bioavailability of CBD, thus helping to maximize its therapeutic potential. A variety of approaches are now emerging, including nanoemulsion-based systems, lipid-based formulations, prodrugs, nanocarriers, and alternative routes of administration, which hold promise for improving the bioavailability of CBD and pave the way for novel formulations that maximize the therapeutic potential of CBD in various medical conditions. This opinion piece presents the current understanding surrounding CBD bioavailability and considers strategies aimed at improving both its absorption and its bioavailability.
Identifiants
pubmed: 37833962
pii: ijms241914514
doi: 10.3390/ijms241914514
pmc: PMC10572536
pii:
doi:
Substances chimiques
Cannabidiol
19GBJ60SN5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bod Science Ltd
ID : 2023
Références
Int J Pharm. 2020 Jan 25;574:118916
pubmed: 31811927
Drugs. 2021 Sep;81(13):1513-1557
pubmed: 34480749
Cannabis Cannabinoid Res. 2022 Oct;7(5):561-568
pubmed: 34918950
AAPS PharmSciTech. 2009;10(3):858-63
pubmed: 19562489
J Cannabis Res. 2022 Apr 17;4(1):23
pubmed: 35430807
J Control Release. 2012 Aug 10;161(3):927-32
pubmed: 22580111
Medicines (Basel). 2019 Feb 23;6(1):
pubmed: 30813390
Pharmaceutics. 2021 Dec 13;13(12):
pubmed: 34959427
Molecules. 2016 Dec 25;22(1):
pubmed: 28029138
Molecules. 2021 Mar 08;26(5):
pubmed: 33800445
J Gen Intern Med. 2021 Jul;36(7):2074-2084
pubmed: 33515191
Pharmacol Ther. 2013 Apr;138(1):18-37
pubmed: 23261685
Gels. 2022 May 29;8(6):
pubmed: 35735678
J Control Release. 2017 Nov 28;266:1-7
pubmed: 28890215
Pharmacol Ther. 2017 Jul;175:133-150
pubmed: 28232276
Eur Neuropsychopharmacol. 2017 Dec;27(12):1223-1237
pubmed: 29129557
Psychopharmacology (Berl). 2021 Jan;238(1):9-28
pubmed: 33221931
Ageing Res Rev. 2021 Dec;72:101487
pubmed: 34662745
J Control Release. 2003 Dec 12;93(3):377-87
pubmed: 14644587
J Pharm Sci. 2018 May;107(5):1423-1429
pubmed: 29287930
Mol Pharm. 2019 May 6;16(5):1999-2010
pubmed: 30865462
J Neurodev Disord. 2019 Aug 2;11(1):16
pubmed: 31370779
P T. 2017 Mar;42(3):180-188
pubmed: 28250701
Eur J Pharm Sci. 2017 Nov 15;109:21-30
pubmed: 28736128
Epilepsy Behav. 2019 Sep;98(Pt A):233-237
pubmed: 31394352
Int J Mol Sci. 2020 Sep 14;21(18):
pubmed: 32937917
Saudi Pharm J. 2021 Sep;29(9):1029-1042
pubmed: 34588849
J Am Pharm Assoc (2003). 2020 Jan - Feb;60(1):225-234.e6
pubmed: 31495691
Clin Pharmacol Drug Dev. 2018 Sep;7(7):751-758
pubmed: 29125702
Int J Pharm. 2021 Nov 20;609:121159
pubmed: 34624443
Molecules. 2019 Aug 16;24(16):
pubmed: 31426272
Adv Ther. 2019 Nov;36(11):3196-3210
pubmed: 31512143
Epilepsy Res. 2019 Aug;154:13-20
pubmed: 31022635
CNS Drugs. 2020 Aug;34(8):795-800
pubmed: 32504461
Cannabis Cannabinoid Res. 2023 Apr 25;:
pubmed: 37098174
Front Chem. 2021 Nov 08;9:754832
pubmed: 34820356
Front Vet Sci. 2022 Apr 28;9:892306
pubmed: 35573415
Molecules. 2022 Sep 17;27(18):
pubmed: 36144803
Eur J Pharm Biopharm. 2019 Jan;134:126-137
pubmed: 30472144
Curr Drug Metab. 2016;17(3):206-26
pubmed: 26651971
Pharmaceutics. 2022 Mar 26;14(4):
pubmed: 35456540
Pharm Res. 2008 Oct;25(10):2334-44
pubmed: 18560998
J Pharm Sci. 2007 Feb;96(2):312-9
pubmed: 17051591
Front Pharmacol. 2018 Nov 26;9:1365
pubmed: 30534073
Basic Clin Pharmacol Toxicol. 2022 Apr;130(4):439-456
pubmed: 35083862
Molecules. 2020 Jul 28;25(15):
pubmed: 32731371
Int J Pharm. 2022 Apr 5;617:121627
pubmed: 35245638
Antioxidants (Basel). 2019 Dec 25;9(1):
pubmed: 31881765
Pharmaceutics. 2022 Jul 14;14(7):
pubmed: 35890362
J Biol Chem. 2015 Apr 3;290(14):8711-21
pubmed: 25666611
Int J Pharm. 2018 Jan 15;535(1-2):272-284
pubmed: 29138045
AAPS PharmSciTech. 2019 Feb 27;20(3):129
pubmed: 30815765
Mater Sci Eng C Mater Biol Appl. 2018 Nov 1;92:1041-1060
pubmed: 30184728
AAPS PharmSciTech. 2022 Mar 14;23(3):85
pubmed: 35288801
Metabolites. 2022 Dec 10;12(12):
pubmed: 36557285
Nanomaterials (Basel). 2020 Jul 19;10(7):
pubmed: 32707641
Int J Pharm. 2020 May 15;581:119276
pubmed: 32243971
Cells. 2021 May 19;10(5):
pubmed: 34069407
Sci Rep. 2020 Feb 28;10(1):3697
pubmed: 32111858
Alcohol Clin Exp Res. 2020 Feb;44(2):340-353
pubmed: 31803950
Med Cannabis Cannabinoids. 2022 Jul 25;5(1):102-119
pubmed: 36467783
Pharmaceutics. 2020 May 09;12(5):
pubmed: 32397428
Molecules. 2019 Sep 19;24(18):
pubmed: 31546753
Int J Mol Sci. 2019 Feb 02;20(3):
pubmed: 30717337
Eur J Pharm Sci. 2005 Sep;26(1):71-7
pubmed: 15955678
J Control Release. 2021 Jun 10;334:427-451
pubmed: 33964365
Adv Pharmacol. 2017;80:67-134
pubmed: 28826544
Pharmaceuticals (Basel). 2020 Aug 28;13(9):
pubmed: 32872355
Pharmaceutics. 2022 Nov 08;14(11):
pubmed: 36365225
Molecules. 2018 Sep 27;23(10):
pubmed: 30262735
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6375-80
pubmed: 19307565
Foods. 2022 Jan 27;11(3):
pubmed: 35159526
Pharmaceutics. 2021 Mar 19;13(3):
pubmed: 33808893
J Diet Suppl. 2020;17(5):517-526
pubmed: 32543253
Thorax. 2023 Sep;78(9):922-932
pubmed: 36823163
Expert Opin Drug Deliv. 2021 Nov;18(11):1577-1587
pubmed: 34253133